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We compared the incidence of bacterial pneumonia among
336 patients who discontinued trimethoprim-sulfamethox-
azole (TMP-SMX) as prophylaxis against Pneumocystis car-
inii pneumonia (PCP) with that among 75 patients who ful-
filled the criteria for discontinuation but continued receiving
prophylaxis. The difference in the overall incidence rates for
the 2 groups (1.2 events per 100 person-years) was not sta-
tistically significant. Discontinuation of TMP-SMX prophy-
laxis against PCP is not associated with a significant increase
in the incidence of bacterial pneumonia among patients with
a sustained CD4 cell count increase to 1200 cells/mL.
The risk for bacterial pneumonia is substantially increased
among patients with HIV infection [1, 2], and bacterial pul-
monary infections are a major cause of morbidity among HIV-
positive individuals, especially patients who are injection drug
users [3, 4]. The mortality associated with bacterial pneumonia
is substantial, especially among patients with advanced stages
of HIV infection [1, 5].
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The incidence of bacterial pneumonia depends on the case
mix within cohorts and increases significantly with advancing
immunodeficiency [6]. In 1995, Hirschtick et al. [1] reported
an overall incidence of 5.5 cases of bacterial pneumonia per
100 person-years among HIV-positive individuals, compared
with 0.9 cases per 100 person-years among HIV-negative in-
dividuals. The risk factors for bacterial pneumonia in HIV-
positive individuals include a low CD4 count, injection drug
use, cigarette smoking, and a history of bacterial pneumonia
[1].
In 1990, use of trimethoprim-sulfamethoxazole (TMP-SMX)
as chemoprophylaxis was recommended for patients who had
experienced recurrent pulmonary bacterial infection [4]. In
1995, Hirschtick et al. [1] were the first to report a considerable
reduction (67%) in the incidence of bacterial pneumonia
among HIV-infected individuals receiving prophylaxis with
TMP-SMX [1].
The influence of antiretroviral combination therapy on the
incidence of bacterial pneumonia is not well defined. However,
there seems to be significant decrease in the incidence of bac-
terial pneumonia after the introduction of potent antiretroviral
combination therapy [7, 8]. In a multivariate model in one
study, prophylaxis with TMP-SMX did not further reduce the
risk of bacterial pneumonia [8]. Nevertheless, bacterial pneu-
monia remained an important cause of morbidity in these stud-
ies [7, 8]. For patients who have a sustained increase in the
CD4 cell count while receiving successful antiretroviral com-
bination therapy, discontinuation of primary prophylaxis
against Pneumocystis carinii pneumonia (PCP) is safe with re-
gard to the associated risk for PCP [9–13].
The incidence of suspected or confirmed bacterial pneu-
monia was 3.1 cases per 100 person-years among patients in
Switzerland who discontinued PCP prophylaxis [14]; a similar
rate was noted in an American study [10]. In recently published
randomized trials of discontinuation of primary PCP prophy-
laxis, there was no evidence of an increased risk of bacterial
pneumonia among patients who discontinued prophylaxis [11,
12]. However, because of the low incidence of bacterial pneu-
monia, the power of these studies was limited. The aim of the
present study was to assess the influence of withdrawal of TMP-
SMX–based primary PCP prophylaxis on the incidence of com-
munity-acquired pneumonia (CAP) among patients receiving
antiretroviral combination therapy.
Patients and methods. The Swiss HIV Cohort Study
(SHCS) is a prospective cohort study with continuing enroll-
ment of HIV-1–infected patients [15]. Follow-up of patients
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16 years of age is done at 1 of 7 outpatient clinics. Enrollment
is independent of the stage of disease or the degree of im-
munosuppression, and information is collected, according to
standardized criteria, at registration and at follow-up visits
every 6 months. Clinical status is defined according to the 1993
classification system for HIV infection established by the Cen-
ters for Disease Control and Prevention (CDC; Atlanta, GA).
The CD4 cell count is measured using flow cytometry. Plasma
HIV RNA levels are measured using the Roche Amplicor assay,
which has a lower limit of detection of ∼200 copies/mL. An
ultrasensitive modification of the assay, which had a limit of
detection of 2–40 copies/mL, was introduced in 1998 [16].
Two groups of patients enrolled in the SHCS were selected
for the present study. Group I included patients who discon-
tinued receiving primary prophylaxis against PCP. All 396 par-
ticipants in a study of the discontinuation of primary prophy-
laxis against PCP (i.e., the StopCox1 study [14]) were
potentially eligible for analysis. This study enrolled patients
from June 1997 through October 1999, and data from follow-
up that lasted until the end of 1999 were included in the anal-
ysis. All patients had to have a sustained increase in the CD4
cell count (to 200 cells/mL; 14% of the total lymphocyte
count) that lasted for 12 weeks before discontinuation of PCP
prophylaxis. For 60 patients (15%), the type of prophylaxis that
was discontinued was not TMP-SMX prophylaxis; these 60
patients were excluded from the analysis. Therefore, group I
consisted of 336 patients.
Group II included patients who continued receiving pro-
phylaxis despite having elevated CD4 cell counts. A total of 82
patients fulfilled the criteria for discontinuation of PCP pro-
phylaxis at the end of enrollment in the StopCox1 study but
continued receiving PCP prophylaxis. Of those 82 patients, 75
(92%) were receiving TMP-SMX and constituted group II in
the analysis. The earliest start date for follow-up of group II
was 1 July 1997, and the latest end date for follow-up was 15
March 2001.
The primary end point of the present study was diagnosis
of CAP. “CAP” was defined as the occurrence of symptoms of
acute lower respiratory infection in association with the pres-
ence of an infiltrate on a chest radiograph. The presence of
symptoms of acute lower respiratory infection with clinical
findings consistent with pneumonia (but without radiological
signs of pneumonia) was not accepted as a definition of pneu-
monia. We studied the incidence of CAP in the 2 groups.
Patients in group I were followed from the date that primary
prophylaxis was discontinued to the date of death, the date of
loss to follow-up, or the date of the end of the StopCox1 study.
The data for group II had to be collected retrospectively because
single episodes of pneumonia are not recorded in the SHCS
database. The patients’ medical charts were reviewed by mem-
bers of the SHCS during February and March 2001. Complete
follow-up was calculated from the date when patients would
have fulfilled the entry criteria for StopCox1 until the date of
death, the date of discontinuation of TMP-SMX prophylaxis,
or the date of last contact with the patient. The earliest follow-
up start date for patients in group II was 1 July 1997, and the
last censor date was 15 March 2001.
Incidence rates were assessed assuming a Poisson distribution
of events. The difference in the incidence rates between the 2
groups and the corresponding 95% CI were calculated. A 2-
sided P value of !.05 was considered statistically significant.
We used Stata software, version 6.0 (Stata), for analyses.
Results. Characteristics of the patients studied are shown
in table 1. There were no statistically significant differences
between patients who were enrolled in the study and patients
who were not enrolled, with respect to age, sex, the type of
regimen that included a protease inhibitor, and plasma HIV
RNA level. Patients in group II had a history of more advanced
immunodeficiency (with more patients in group II with clinical
stage C, according to the CDC classification) and lower nadir
CD4 cell counts, compared with patients in group 1. The ab-
solute CD4 cell count at the beginning of the study was sig-
nificantly lower in group II than in group I, although there
was no difference between the 2 groups with regard to the
percentage of CD4 cells.
For group I, the median duration of follow-up was 1.5 years,
which was significantly longer than that for group II (0.84
years); total length of follow-up was 471 person-years for group
I and 77 person-years for group II. Four patients in group I
died during follow-up; 1 died of hepatocellular carcinoma; 1,
of non-Hodgkin lymphoma; 1, of a heroin overdose; and 1, of
sudden death (probably cardiac arrest). Two patients in group
II died during the study: 1 patient committed suicide, and 1
died of a heroin overdose. Follow-up of 60 persons in group
II (80%) had to be censored before the date of chart review
because these patients had discontinued receiving TMP-SMX
after the results of the StopCox1 study became available.
Twelve patients in group I had CAP. Four of these 12 patients
had a history of injection drug use; 4 patients had stage C
clinical status and 7 had stage B clinical status, according to
CDC classification. The nadir CD4 cell count was !100 cells/
mL for 8 of these patients. One patient in group II who had
stage B clinical status (according to CDC classification), a his-
tory of injection drug use, and a nadir CD4 cell count of 68
cells/mL developed CAP during the study. An etiological di-
agnosis was possible for only 2 episodes of CAP: Streptococcus
pneumoniae was found in the blood culture of 1 patient, and
1 case of pneumonia was thought to have been caused by
Haemophilus influenzae that was found abundantly in a sputum
sample. All episodes of CAP responded well to antibacterial
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Table 1. Characteristics, at baseline, of participants in a study comparing the incidence of
community-acquired pneumonia among patients who discontinued trimethoprim-sulfamethoxazole
(TMP-SMX) prophylaxis against Pneumocystis carinii pneumonia (group I) with that among patients
who continued receiving such prophylaxis (group II).
Characteristic
Group I
(n p 336)
Group II
(n p 75) P valuea
Age, median years (IQR) 37 (34–45) 37 (33–41) .3381
Male sex 236 (70.2) 45 (60.0) .085
Transmission group .192
Men who have sex with men 127 (38.0) 20 (26.7)
Heterosexual contact 94 (28.0) 21 (28.0)
Injection drug use 104 (31.0) 32 (42.7)
Other or unknown 11 (3.3) 2 (2.7)
CDC clinical stageb !.001
A 92 (27.4) 8 (10.7)
B 166 (49.4) 35 (46.7)
C 78 (23.2) 32 (42.3)
Antiretroviral regimen containing a PI 290 (86.3) 62 (82.7)
CD4 cell count, median cells/mL (IQR) 326 (273–403) 294 (248–371) .002
CD4 cell percentagec (IQR) 22 (18–26) 21 (17–25) .930
Nadir CD4 cell count, median cells/mL (IQR) 104 (57–144) 75 (31–129) .008
Virus load, median log10 copies/mL (IQR) 1.70 (1.70–2.90) 2.00 (1.70–3.00) .884
Duration of TMP-SMX prophylaxis,d
median days (IQR) 757 (464–1151) 1038 (556–1718) .024
Follow-up, median years (IQR) 1.53 (0.83–1.93) 0.84 (0.33–1.57) !.0001
NOTE. Data are no. (%) of study participants, unless otherwise indicated. CDC, Centers for Disease Control and
Prevention (Atlanta, GA); IQR, interquartile range; PI, protease inhibitor.
a By the Wilcoxon rank sum test, for numerical data; by test, for categorical data.2x
b As defined by the 1993 CDC classification system for HIV infection.
c Percentage of the total lymphocyte count.
d Before the start of the study.
drugs given for no longer than 14 days (b-lactam antibiotics
were given to 9 patients, and macrolides were given to 4 pa-
tients). For 5 of the patients, previous vaccination against S.
pneumoniae had been recorded on the medical chart.
Follow-up and incidence data for the 2 groups are shown
in table 2. For both groups, the incidence of CAP was !3 cases
per 100 person-years of follow-up. Although the point estimate
of the CAP incidence rate was 49% lower in the group that
continued receiving prophylaxis, compared with the group that
discontinued prophylaxis, the difference was far from statisti-
cally significant because of the very low absolute risk.
Discussion. The present study demonstrates a low inci-
dence of CAP among HIV-infected persons who are receiving
successful antiretroviral combination therapy and who have a
sustained increase in the CD4 cell count to 200 cells/mL. This
effect was observed regardless of whether TMP-SMX prophy-
laxis was continued or interrupted. In fact, CAP incidence rates
for the studied populations with CD4 cell counts of mainly
200–500 cells/mL were in the range of the CAP incidence rates
noted for patients in a large cohort who had CD4 cell counts
of 1500 cells/mL before potent antiretroviral combination ther-
apy became available [1].
The main limitation of the present study is the comparison
of nonrandomized groups. For example, patients in group II
had a slightly lower nadir CD4 cell count than did patients in
group I. Therefore, we cannot exclude a bias toward discon-
tinuation of prophylaxis for patients with a lower risk of pneu-
monia. In addition, the total follow-up in the group that con-
tinued receiving prophylaxis was limited, mainly because of the
interruption of TMP-SMX prophylaxis, once data from the
StopCox1 study were available. Another limitation of the pre-
sent study is the different nature of data collection for the 2
study groups; collection was done prospectively for group I and
retrospectively for group II. This could have led to underes-
timation of the incidence of CAP in group II.
However, the results of the present study are in concordance
with the observations of Sullivan et al. [8], who reported a
significantly reduced risk of bacterial pneumonia among HIV-
infected patients who were receiving protease inhibitor–based
antiretroviral therapy independently of PCP prophylaxis. In 2
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Table 2. Follow-up for and incidence of community-acquired
pneumonia (CAP) among patients who discontinued trimetho-
prim-sulfamethoxazole prophylaxis against Pneumocystis car-
inii pneumonia (group I) and those who continued receiving
such prophylaxis (group II).
Finding
Group I
(n p 336)
Group II
(n p 75)
Total follow-up, person-years 472 77
CAP episodes, no. 12 1
Incidence ratea (95% CI) 2.5 (1.3–4.4) 1.3 (0.03–7.2)
a No. of CAP cases per 100 person-years. The difference in the incidence
rates between groups I and II was 1.2 CAP cases per 100 person-years
(95% CI, 1.6 to 4.1) ( ).P p .6
recently published randomized trials of discontinuation of pri-
mary prophylaxis, the incidence of bacterial pneumonia was
low in both arms of the study, and there was no statistically
significant difference in the incidence of CAP between the 2
patient groups [11, 12].
Injection drug use has been a risk factor for bacterial pneu-
monia in most cohorts of HIV-infected patients studied to date
[1, 6, 8, 17]. A history of injection drug use was not associated
with a higher risk of CAP in our study. However, drug sub-
stitution programs are widely used in Switzerland, which leads
to better social situations for injection drug users, which might
diminish the risk of CAP.
Discontinuation of PCP prophylaxis has been proven safe
with regard to risk of PCP if there is a sustained increase in
the CD4 cell count during antiretroviral combination therapy
[9, 13, 18]. There remain concerns about safety with regard to
the risk of bacterial pneumonia.
The present study adds to the evidence that an increase in
the risk of CAP after discontinuation of TMP-SMX is, at most,
minimal. A quite hypothetical advantage of continuing use of
a prophylactic antibiotic is outweighed by the disadvantages of
side effects, pill burden, and development of bacterial resistance
in a population [19].
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15. Sudre P, Rickenbach M, Taffé P, Janin P, Volkart AC, Francioli P. Clinical
epidemiology and research on HIV infection in Switzerland: the Swiss
HIV Cohort Study 1988–2000. Schweiz Med Wochenschr 2000; 130:
1493–500.
16. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels
in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:
179–83.
HIV/AIDS • CID 2003:36 (1 April) • 921
17. Boschini A, Smacchia C, Di Fine M, et al. Community-acquired pneu-
monia in a cohort of former injection drug users with and without
human immunodeficiency virus infection: incidence, etiologies, and
clinical aspects. Clin Infect Dis 1996; 23:107–13.
18. Trikalinos TA, Ioannidis JP. Discontinuation of Pneumocystis carinii
prophylaxis in patients infected with human immunodeficiency virus:
a meta-analysis and decision analysis. Clin Infect Dis 2001; 33:1901–9.
19. Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK,
Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resis-
tance in the AIDS era. J Infect Dis 1999; 180:1809–18.
